The majority of the approved recombinant enzymes are produced in CHO cells (β-glucorebrosidase for Gaucher disease, α-galactosidase for Fabry disease, α-mannosidosidase for α-mannosidosis, sulfatases for mucopolysaccharidosis, α-glucosidase for Pompe disease, digestive enzymes), some in E. coli (E. coli urate oxidase to treat Gout and asparaginase for lymphoblastic leukemia), and S. cerevisiae (S. cerevisiae urate oxidase for the treatment of hyperuricemia) (Walsh, 2018; Taipa et al., 2019) (Table 1). This evidence concerns the gene UOX and hyperuricemia.